Microbion is a clinical stage pharmaceutical company focused on developing a novel class of microbial bioenergetic inhibitors to treat resistant and difficult-to-treat infections. The company's lead therapeutic candidate, Pravibismane, is the first in a new class of anti-infective drugs with broad-spectrum activity and a unique mechanism of action that disrupts microbial cellular metabolism. This drug has shown an unprecedented ability to prevent and eradicate biofilms, which are communities of microorganisms that contribute to chronic infections. Microbion's current clinical programs include two Phase 2 trials for the topical treatment of diabetic foot ulcer infections and orthopedic device-related infections, as well as a preclinical program for the inhalation treatment of chronic lung infections. The company primarily serves the healthcare sector, targeting patients with chronic and resistant infections. Microbion operates in the pharmaceutical market, leveraging a business model that focuses on research and development, clinical trials, and eventual commercialization of its therapeutic candidates. Revenue is generated through partnerships, licensing agreements, and future sales of approved drugs.

Keywords: microbial bioenergetic inhibitors, chronic infections, resistant infections, Pravibismane, biofilms, diabetic foot ulcer, orthopedic device infection, chronic lung infection, clinical trials, pharmaceutical development.